drugset / Trial / NCT04543279
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Phase 2
Terminated
3 enrolled
Washington University School of Medicine
Rigel Pharmaceuticals · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet \<50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib. Additionally, fostamatinib monotherapy may also improve myelofibrosis related symptoms and splenomegaly.
Timeline
- Start
- 2021-05-03
- Primary completion
- 2022-07-01
- Completion
- 2022-07-30
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fostamatinib | Small molecule | 100 mg | — |
| Subject | Fostamatinib | Small molecule | 150 mg | — |
| Subject | Ruxolitinib | Small molecule | — | — |